Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-30
2011-10-18
Li, Ruixiang (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
08039436
ABSTRACT:
A polypeptide, the amino acid sequence of which comprises a sequence as set forth in SEQ ID NO:2, including at least one mutation within the degron domain of the polypeptide encompassed between positions 1 and 35 of the sequence, wherein said at least one mutation reduces the susceptibility of the polypeptide to ubiquitin-proteasome degradation.
REFERENCES:
patent: 6812339 (2004-11-01), Venter et al.
Harvey et al., Embryonic expression andnuclear localization of Xenopus homeobox (Xhox) gene products. The EMBO Journal 5:1237-1244, 1986.
Amsellem et al., “Ex Vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein”, Nat. Med., (2003), 1423-1427, vol. 9, No. 11.
Antonchuk et al., “HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation”, Exp Hematol., (2001), 1125-1134, vol. 29.
Antonchuk et al., “HOXB4-Induced Expansion of Adult Hematopoietic Stem Cells Ex Vivo”, Cell, (2002), 39-45, vol. 109.
Beslu et al., “Molecular interactions involved in HOXB4-induced activation of HSC self-renewal”, Blood, (2004), 2307-2314, vol. 104, No. 8.
Bhardwaj et al., “Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation”, Nat. Med., (2001), 172-180, vol. 2, No. 2.
Buske et al., “Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells”, Blood, (2002), 862-868, vol. 100.
Cellot et al., “Sustained in vitro trigger of self-renewal divisions in HOXB4hi PBX1lo hematopoietic stem cells”, Exp Hematol., (2007), 802-816, vol. 35.
Chowdary et al., “Accumulation of p53 in a Mutant Cell Line Defective in the Ubiquitin Pathway”, Mol. Cell. Biol., (1994), 1997-2003, vol. 14, No. 3.
Corish et al., “Attenuation of green fluorescent protein half-life in mammalian cells”, Protein Engineering, (1999), 1035-1040, vol. 12, No. 12.
Coulombe et al., “Rapid Turnover of Extracellular Signal-Regulated Kinase 3 by the Ubiquitin Proteasome Pathway . . . ”, Mol. Cell. Biol., (2003), 4542-4558, vol. 23, No. 13.
de Haan et al., “In Vitro Generation of Long-Term Repopulating Hematopoietic Stem Cells by Fibroblast Growth Factor-1”, Dev. Cell., (2003), 241-251, vol. 4.
Gabellini et al., “Early mitotic degradation of the homeoprotein HOXC10 is potentially linked to cell cycle progression”, Embo Journal, (2003), 3715-3724, vol. 22, No. 14.
Hershko et al., “The Ubiquitin System”, Annu. Rev. Biochem., (1998), 425-479, vol. 67.
Karanu et al., “The Notch Ligand Jagged-1 represents a novel growth factor of Human Hematopoietic Stem Cells”, J. Exp. Med.-Rockfeller Univ, (2000), 1365-1372, vol. 192-No. 9.
Kroon et al., “HOXA9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b”, EMBO J., (1998), 3714-3725, vol. 17-No. 13.
Kroon et al., “NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice”, EMBO J., (2001), 350-361, vol. 20, No. 3.
Krosl et al., “Human hematopoietic stem cells can be expanded ex vivo using recombinant TAT-HOXB4 protein”, Biology of Blood and Marrow Transplantation. (2005a); 11:19.
Krosl et al., “In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein”, Nat Med, (2003), 1428-1432, vol. 9—No. 11.
Krosl et al., “The Competitive Nature of HOXB4-Transduced HSC is limited by PBX1: The Generation of Ultra-Competitive . . . ”, Immunity by Cell Press, (2003), 561-571 vol. 18.
Lawrence et al., “Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid . . . ”, Blood, (1997), 1922-1930, vol. 89.
Meinnel et al., “Impact of the N-terminal amino acid on targeted protein degradation”, Biol. Chem., (2006), 839-851, vol. 387.
Nagahara et al., “Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27kipl induces cell migration”, Nat Med, 1998, 1449-1452, vol. 4-No. 12.
Ohh et al., “An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells”, EMBO rep., 2002, 177-182, vol. 31-No. 21.
Ory et al., “A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis . . . ”, Proc. Nat. Acad. Sci. USA, (1996), 11400-11406.
Pickart et al., “Back to the Future with Ubiquitin”, Cell, 2004, 181-190, vol. 116.
Pilat et al., “HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells”, Proc. Nat. Acad. Sci. USA, (2005), 12101-12106, vol. 102, No. 34.
Schiedlmeier et al., “High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord . . . ”, Blood, 2003, 1759-1768, vol. 101, No. 5.
Schwarze et al., “In vivo protein transduction: Delivery of a Biologically Active Protein into the Mouse”, Science, 1999, 1569-1572, vol. 285.
Thorsteinsdottir et al., “The oncoprotein E2A-Pbx1a collaborates with HOXA9 to acutely transform primary bone marrow cells”, Mol. Cell Biol., 1999, 6355-6366.
Thorsteinsdottir et al., “Overexpression of the myeloid leukemia-associated HOXA9 gene in bone marrow cells induces stem cell expansion”, Blood, 2002, 121-129, vol. 99.
Willert et al., “Wnt proteins are lipid-modified and can act as stem cell growth factors”, Nature, (2003), 448-452, vol. 423.
Zhang et al., “CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein”, EMBO J., (2003), 6057-6067, vol. 22, No. 22.
Beslu Nathalie
Humphries Keith
Roy Denis-Claude
Sauvageau Guy
Adaerata, Limited Partnership
British Columbia Caner Agency Branch
Gauvreau Julie
Goudreau Gage Dubuc
Li Ruixiang
LandOfFree
Mutated HOXB4 proteins with improved stability, and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutated HOXB4 proteins with improved stability, and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutated HOXB4 proteins with improved stability, and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293397